Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 28 (11), 1125-36

Effects of the IMP-dehydrogenase Inhibitor, Tiazofurin, in Bcr-Abl Positive Acute Myelogenous Leukemia. Part I. In Vivo Studies

Affiliations

Effects of the IMP-dehydrogenase Inhibitor, Tiazofurin, in Bcr-Abl Positive Acute Myelogenous Leukemia. Part I. In Vivo Studies

Karim Malek et al. Leuk Res.

Abstract

Six patients with bcr-abl positive AML or chronic myelogenous leukemia in blast crisis (CML-BC) were treated with the IMP-dehydrogenase (IMPDH) inhibitor, Tiazofurin, in a Phase-II trial. Tiazofurin was given by IV infusion (2200-2700 mg/m2 per day) for up to 10 days. Leukemia blasts rapidly disappeared from the circulation of patients during treatment, while mature myeloid cells in the marrow increased in number. Although these hematologic responses were transient, persisting less than 3-4 weeks, our findings confirm that Tiazofurin has anti-leukemia activity. This drug warrants further study in combination regimens with other chemotherapeutic agents for the treatment of bcr-abl positive AML and CML-BC.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

Publication types

Feedback